Pernix Therapeutics to Ring The NASDAQ Stock Market Opening Bell

  Pernix Therapeutics to Ring The NASDAQ Stock Market Opening Bell

Business Wire

THE WOODLANDS, Texas -- January 28, 2013

Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX),
a specialty pharmaceutical company, today announced that it is scheduled to
ring The NASDAQ Stock Market Opening Bell at 9:30 am EST on Monday, January
28, 2013 to celebrate the Company's listing on the NASDAQ Global Market. The
Company’s common stock will begin trading on the NASDAQ on January 28, 2013.

Access to the NASDAQ MarketSite webcam feed is available to view the ceremony
live by launching this link,
http://www.nasdaq.com/about/marketsitetowervideo.asx at 9:20 a.m. EST. To
watch, under the heading MarketSite at the bottom of the page click on Windows
Media Player.

Cooper Collins, President and CEO of Pernix, said, “We are pleased to ring the
NASDAQ Opening Bell, celebrating our new listing and recent completion of the
acquisition of Cypress Pharmaceuticals and Hawthorn Pharmaceuticals.”

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded
products, including the recently acquired Hawthorn Pharmaceuticals’ product
line. The Company’s branded products for the pediatrics market include CEDAX®,
an antibiotic for middle ear infections, NATROBA™, a topical treatment for
head lice marketed under an exclusive co-promotion agreement with ParaPRO,
LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX®
and PEDIATEX®). The Company’s branded products for gastroenterology include
OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer
disease, and REZYST™, a probiotic blend to promote dietary management. The
Company promotes its branded pediatric and gastroenterology products through
its sales force. Pernix markets its generic products through its wholly-owned
subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The
Company’s wholly-owned subsidiary, Great Southern Laboratories, manufactures
and packages products for the pharmaceutical industry in a wide range of
dosage-forms. A product candidate utilizing cough-related intellectual
property is in development for the U.S. OTC market. Founded in 1996, the
Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company’s website
located at www.pernixtx.com.

Cautionary Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements including
words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,”
“anticipate,” “believe,” “seek,” “target” or similar expressions are
forward-looking statements. Because these statements reflect the Company’s
current views, expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties. No assurances can
be given regarding the Company’s future performance. Investors should note
that many factors, as more fully described under the caption "Risk Factors" in
our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange
Commission and as otherwise enumerated herein or therein, could affect the
Company’s future financial results and could cause actual results to differ
materially from those expressed in forward-looking statements. The
forward-looking statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate, could cause
our actual results to differ materially from expected and historical results.
The Company assumes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future developments or
otherwise.

Contact:

Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, (800) 793-2145 ext. 3002
Director, Investor Relations
jschepers@pernixtx.com
 
Press spacebar to pause and continue. Press esc to stop.